ALX Oncology (ALXO) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ALX Oncology (ALXO) has outperformed Jyong Biotech (MENS) over the past year, losing 35.6% versus a loss of 96.1%. ALX Oncology is the larger company by market cap ($172.8 million vs $159.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | MENS |
|---|---|---|
| Share price | $1.25 | $2.10 |
| Market cap | $172.85M | $159.66M |
| 1-day change | +5.93% | 0.00% |
| YTD return | +10.62% | -46.84% |
| 1-year return | -35.57% | -96.12% |
| 5-year return | -97.88% | — |
| EPS (TTM) | $-1.13 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $63.00 |
| 52-week low | $1.05 | $1.43 |
| Distance from 52-week high | -53.01% | -96.67% |
| Analyst consensus | none | — |
| Avg. price target upside | +268.00% | — |
| Average volume | 1.05M | 45.47K |
| Shares outstanding | 138.28M | 74.23M |
| Employees | 48 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed MENS by 60.5 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
ALXO vs MENS FAQ
Which is bigger, ALX Oncology or Jyong Biotech?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, ALXO or MENS?
ALXO returned -35.57% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.